Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad
More articles/Ad
More articles
-
UK pharma latest high rated company to hit the euro market this week -
Rise of mRNA technology was a gamechanger for the sector, says analyst
-
Vaccine maker issued shares in oversubscribed deal to fund acquisition
-
-
Existing shareholders took a large chunk of the deal, 30% of bidders left empty-handed
-
Calmer book builds than earlier trades hint at less guesswork over pricing
